Table 2.

Evaluation of remaining patients after 12 years

	DBS (n = 11/15)	Drug-treated group (n = 9/14)	Statistical differences
Age at final evaluation	74 ± 8.2	76 ± 7.1	p = 0.8
Deaths and causes	4 Cancer (2) Heart failure (2)	3 Cancer (1) Inhalation pneumonia (2)
Best UPDRS III	24.2 ± 11.2	29.3 ± 10.3	p = 0.03
Worst UPDRS III	62 ± 13.1	65 ± 11.1	p = 0.6
UPDRS-IV (dyskinesia)	3.9 ± 1.1	6.3 ± 1.3	p < 0.001
Percentage daytime “off”	28 ± 14	38 ± 15	p = 0.15
Best Schwab and England	74 ± 14	72 ± 11	p = 0.8
Worst Schwab and England	43 ± 11	39 ± 13	p = 0.5
LEDD (mg)	655 ± 132	845 ± 128	p = 0.03
PDQ-39 scores at end of study (raw)	32.2 ± 11.2	35.8 ± 14.8	p = 0.5
Patients still at home	7/11	5/9	p = 0.8

Significant differences in bold, Mann–Whitney

In the DBS group, measurements made “on stimulation, on medications”, in the drug-treated group, measurements made “on medications”